Strategy for allergic diseases treatment based on the function of ayurvedic medicines

2016 Fiscal Year Final Research Report

• Project/Area Number: 26305004
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 海外学術
• Research Field: Natural medicines
• Research Institution: The University of Tokushima
• Principal Investigator: FUKUI Hiroyuki 徳島大学, 大学院医歯薬学研究部, 特任教授 (90112052)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 花粉症 / アレルギー性鼻炎 / アレルギー疾患 / ヒスタミン / 天然物医薬 / 疾患感受性遺伝子 / 細胞内シグナル / PKCδ

Outline of Final Research Achievements

A novel benzofuran compound 4-methoxybenzofuran-5-carboxamide (HMBC) was identified as an active ingredient from anti-allergic ayurvedic medicine Tephresia purpurea. MBCA suppressed H1 R gene expression through suppression of PKCd activation. In addition, MBCA isomer showed stronger H1R gene expression inhibitory activity than MBCA. In allergy model rats, it was found that MBCA ameliorates nasal symptoms through suppressing expression of H1R gene and Th2 cytokine gene such as IL-4, IL-5 of nasal mucosa. Furthermore, since MBCA suppresses IL-33 gene expression, it is suggested that not only acute symptoms of allergic rhinitis but also chronic symptoms may be improved by MBCA.

Free Research Field

薬理学